Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study

BACKGROUND: GLP-1 receptor agonists (GLP-1 RA) and SGLT-2 inhibitors (SGLT-2i) have shown to reduce the risk of major adverse cardiovascular events (MACE), death and worsening nephropathy when added to standard of care. However, these two dug classes differ in efficacy and safety. We compared the ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Baviera, Marta, Foresta, Andreana, Colacioppo, Pierluca, Macaluso, Giulia, Roncaglioni, Maria Carla, Tettamanti, Mauro, Fortino, Ida, Genovese, Stefano, Caruso, Irene, Giorgino, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400295/
https://www.ncbi.nlm.nih.gov/pubmed/35999556
http://dx.doi.org/10.1186/s12933-022-01572-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400295/
https://www.ncbi.nlm.nih.gov/pubmed/35999556
http://dx.doi.org/10.1186/s12933-022-01572-y

Ejemplares similares